<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896645</url>
  </required_header>
  <id_info>
    <org_study_id>CHLA-20-00013</org_study_id>
    <nct_id>NCT04896645</nct_id>
  </id_info>
  <brief_title>Albuterol Integrated Adherence Monitoring in Children With Asthma</brief_title>
  <official_title>Albuterol Integrated Adherence Monitoring in Children With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to evaluate whether an integrated electronic adherence monitoring&#xD;
      albuterol rescue inhaler can improve proper use in a mostly minority and inner-city&#xD;
      population of children treated for asthma at the Children's Hospital of Los Angeles&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to (1) determine whether an integrated EAM albuterol rescue inhaler&#xD;
      can increase proper use (2) determine if the monitoring capabilities of the device (flow&#xD;
      rate, warnings) and/or increased proper use from having the device correlate with better&#xD;
      outcomes. The investigators will also have patients perform at-home gamified spirometry&#xD;
      (Aluna ©) to (3) determine if at-home spirometry can predict albuterol use or change&#xD;
      outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Asthma Outcomes</measure>
    <time_frame>3 months</time_frame>
    <description>Severity by NHLBI EPR3 Guidelines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma Adherence</measure>
    <time_frame>3 months</time_frame>
    <description>4-item Morisky Medication Adherence Scale (MMAS-4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma Adherence</measure>
    <time_frame>3 months</time_frame>
    <description>Test of Adherence to Inhalers (TAI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma Outcomes</measure>
    <time_frame>3 months</time_frame>
    <description>Composite Asthma Severity Index (CASI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Asthma Outcomes</measure>
    <time_frame>3 months</time_frame>
    <description>Asthma Control Test (ACT)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albuterol Use</measure>
    <time_frame>3 months</time_frame>
    <description>Questionnaires created by investigators addressing when and how often albuterol is used for symptoms, illness, etc.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spirometry</measure>
    <time_frame>3 months</time_frame>
    <description>Aluna at home gamified spirometer, measures full spirometry FEV1, FVC, FEV1/FVC, Peak Flow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung Function</measure>
    <time_frame>3 months</time_frame>
    <description>Microlife FEV1, measures FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Quality of Life</measure>
    <time_frame>3 months</time_frame>
    <description>PedsQL (Pediatric Quality of Life Inventory)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Asthma in Children</condition>
  <arm_group>
    <arm_group_label>Patients 8 to &lt;19 years of age with a diagnosis of asthma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients 8 to &lt;19 years of age with a diagnosis of asthma as ICD-9 code 493 or ICD-10 code J45 seen in the allergy clinic at CHLA who have an albuterol rescue inhaler already prescribed and access to a personal smartphone will be eligible for recruitment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Digihaler Albuterol Device by TEVA</intervention_name>
    <description>Patient with asthma will have their regular albuterol rescue inhaler replaced with Digihaler, they will also be asked to perform gamified spirometry (Aluna) at home</description>
    <arm_group_label>Patients 8 to &lt;19 years of age with a diagnosis of asthma</arm_group_label>
    <other_name>Electronic Adherence Monitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 8 to &lt;19 years of age with a diagnosis of asthma as ICD-9 code 493 or ICD-10&#xD;
             code J45 seen in the allergy clinic at CHLA who have an albuterol rescue inhaler&#xD;
             already prescribed and access to a personal smartphone will be eligible for&#xD;
             recruitment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to use device, unable to use albuterol (i.e. must use levalbuterol) or&#xD;
             Age &lt; 4 (ProAir® Digihaler only approved for Subjects 4 years and older). Patients&#xD;
             with other chronic lung disease besides asthma or other significant comorbidities that&#xD;
             could affect lung function/asthma (e.g. significant heart defects, immunodeficiency,&#xD;
             cystic fibrosis, etc).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elvira Lopez, BA</last_name>
    <phone>3233617170</phone>
    <email>elvlopez@chla.usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neema Izadi, MD</last_name>
    <phone>3233612501</phone>
    <email>nizadi@chla.usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neema Izadi, MD</last_name>
      <phone>323-361-2501</phone>
      <email>nizadi@chla.usc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Neema Izadi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

